The Role of Gut Microbiota Biomodulators on Mucosal Immunity and Intestinal Inflammation

Abstract

Alterations of the gut microbiota may cause dysregulated mucosal immune responses leading to the onset of inflammatory bowel diseases (IBD) in genetically susceptible hosts. Restoring immune homeostasis through the normalization of the gut microbiota is now considered a valuable therapeutic approach to treat IBD patients. The customization of microbe-targeted therapies, including antibiotics, prebiotics, live biotherapeutics and faecal microbiota transplantation, is therefore considered to support current therapies in IBD management. In this review, we will discuss recent advancements in the understanding of host−microbe interactions in IBD and the basis to promote homeostatic immune responses through microbe-targeted therapies. By considering gut microbiota dysbiosis as a key feature for the establishment of chronic inflammatory events, in the near future it will be suitable to design new cost-effective, physiologic, and patient-oriented therapeutic strategies for the treatment of IBD that can be applied in a personalized manner.

Bacterial infections in lupus: Roles in promoting immune activation and in pathogenesis of the disease

“…For instance, microbial-derived short chain fatty acids, such as butyrate, have been shown to promote development of regulatory T cells [ 45 ]. Microbial dysbiosis, an altered balance of the bacterial microbiota, is common in immune disorders and can lead to expansion of pathogenic and/or opportunistic bacterial species [ [46] , [47] , [48] ]. It is important to note that the composition of the gut microbiome can vary with age and sex of those tested and this must be taken into account in microbiome studies [ 49 , 50 ].…”

Attaching clinical significance to COVID-19-associated diarrhea

“…Over-activated cytokines, immune dysregulation, and inflammatory storms may also cause inflammatory damage to the intestine, leading to diarrhea [ 31 ]. It is noteworthy that as much as 53.4% of patients had detectable viral nucleic acids in their stool samples, suggesting that SARS-CoV-2 might directly damage the intestinal mucosa, causing digestive disturbances, including diarrhea [ 32 ].…”

Gut Microbiota Manipulation as a Tool for Colorectal Cancer Management: Recent Advances in Its Use for Therapeutic Purposes

“…Prebiotics are non-digestible dietary compounds that stimulate the growth and activity of probiotics, conferring a competitive advantage to commensal bacteria capable of metabolizing these substrates or by increasing the production of beneficial metabolic products, such SCFAs, that result from their fermentation [ 129 , 130 ]. The health benefits of prebiotics goes beyond nutrition and they are gaining popularity among people ( Table 3 ).…”

“…Since CRC is characterized by a status of dysbiosis, FMT is considered as a potential clinical application in patients. To date, FMT has only proved to be highly successful in treating recurrent and antibiotic refractory Clostridiodes difficile ( C. difficile ) infection, with cure rates of approximately 90% [ 129 ]. In a CRC mouse model, FMT was able to normalize the gut microbiota through the reduction of tumor growth.…”